nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—ovarian follicle—ovarian cancer	0.0405	0.145	CbGeAlD
Bismuth Subsalicylate—TF—embryo—ovarian cancer	0.0193	0.0693	CbGeAlD
Bismuth Subsalicylate—PTGS1—oviduct—ovarian cancer	0.0186	0.0667	CbGeAlD
Bismuth Subsalicylate—Extravasation—Carboplatin—ovarian cancer	0.016	0.0279	CcSEcCtD
Bismuth Subsalicylate—TF—epithelium—ovarian cancer	0.0158	0.0565	CbGeAlD
Bismuth Subsalicylate—TF—uterine cervix—ovarian cancer	0.0156	0.056	CbGeAlD
Bismuth Subsalicylate—TF—gonad—ovarian cancer	0.0131	0.047	CbGeAlD
Bismuth Subsalicylate—TF—uterus—ovarian cancer	0.013	0.0467	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Carboplatin—ovarian cancer	0.0118	0.0205	CcSEcCtD
Bismuth Subsalicylate—TF—female reproductive system—ovarian cancer	0.0117	0.042	CbGeAlD
Bismuth Subsalicylate—TF—bone marrow—ovarian cancer	0.0111	0.0396	CbGeAlD
Bismuth Subsalicylate—TF—female gonad—ovarian cancer	0.0107	0.0382	CbGeAlD
Bismuth Subsalicylate—TF—vagina—ovarian cancer	0.0106	0.038	CbGeAlD
Bismuth Subsalicylate—TF—testis—ovarian cancer	0.00945	0.0339	CbGeAlD
Bismuth Subsalicylate—Heartburn—Topotecan—ovarian cancer	0.00928	0.0162	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Topotecan—ovarian cancer	0.00902	0.0158	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Vinorelbine—ovarian cancer	0.00772	0.0135	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Topotecan—ovarian cancer	0.00732	0.0128	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Melphalan—ovarian cancer	0.00717	0.0125	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Altretamine—ovarian cancer	0.00687	0.012	CcSEcCtD
Bismuth Subsalicylate—TF—lymph node—ovarian cancer	0.00685	0.0246	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Paclitaxel—ovarian cancer	0.00681	0.0119	CcSEcCtD
Bismuth Subsalicylate—Duodenal ulcer—Docetaxel—ovarian cancer	0.00645	0.0113	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Vinorelbine—ovarian cancer	0.00626	0.0109	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Altretamine—ovarian cancer	0.00626	0.0109	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Melphalan—ovarian cancer	0.00597	0.0104	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Vinorelbine—ovarian cancer	0.00574	0.01	CcSEcCtD
Bismuth Subsalicylate—PTGS2—myometrium—ovarian cancer	0.00569	0.0204	CbGeAlD
Bismuth Subsalicylate—PTGS2—embryo—ovarian cancer	0.00547	0.0196	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Vinorelbine—ovarian cancer	0.00522	0.00911	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Vinorelbine—ovarian cancer	0.00499	0.00872	CcSEcCtD
Bismuth Subsalicylate—Infection—Carboplatin—ovarian cancer	0.00494	0.00863	CcSEcCtD
Bismuth Subsalicylate—ALB—testis—ovarian cancer	0.00492	0.0176	CbGeAlD
Bismuth Subsalicylate—Dizziness—Altretamine—ovarian cancer	0.00476	0.00831	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Topotecan—ovarian cancer	0.00473	0.00826	CcSEcCtD
Bismuth Subsalicylate—PTGS1—epithelium—ovarian cancer	0.00467	0.0168	CbGeAlD
Bismuth Subsalicylate—PTGS1—uterine cervix—ovarian cancer	0.00463	0.0166	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Vinorelbine—ovarian cancer	0.0046	0.00804	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Altretamine—ovarian cancer	0.00458	0.00799	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Melphalan—ovarian cancer	0.00456	0.00796	CcSEcCtD
Bismuth Subsalicylate—Heartburn—Docetaxel—ovarian cancer	0.00453	0.0079	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Docetaxel—ovarian cancer	0.00448	0.00783	CcSEcCtD
Bismuth Subsalicylate—PTGS2—epithelium—ovarian cancer	0.00447	0.016	CbGeAlD
Bismuth Subsalicylate—Deafness—Vinorelbine—ovarian cancer	0.00443	0.00774	CcSEcCtD
Bismuth Subsalicylate—PTGS2—uterine cervix—ovarian cancer	0.00443	0.0159	CbGeAlD
Bismuth Subsalicylate—Nausea—Altretamine—ovarian cancer	0.00428	0.00747	CcSEcCtD
Bismuth Subsalicylate—Pain—Carboplatin—ovarian cancer	0.00426	0.00743	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Paclitaxel—ovarian cancer	0.00421	0.00735	CcSEcCtD
Bismuth Subsalicylate—PTGS1—endometrium—ovarian cancer	0.00419	0.015	CbGeAlD
Bismuth Subsalicylate—Lethargy—Vinorelbine—ovarian cancer	0.00405	0.00707	CcSEcCtD
Bismuth Subsalicylate—PTGS2—endometrium—ovarian cancer	0.00401	0.0144	CbGeAlD
Bismuth Subsalicylate—Hyponatraemia—Vinorelbine—ovarian cancer	0.00398	0.00695	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Carboplatin—ovarian cancer	0.00393	0.00687	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—ovarian cancer	0.00389	0.00679	CcSEcCtD
Bismuth Subsalicylate—PTGS1—uterus—ovarian cancer	0.00386	0.0138	CbGeAlD
Bismuth Subsalicylate—Hearing impaired—Paclitaxel—ovarian cancer	0.00386	0.00674	CcSEcCtD
Bismuth Subsalicylate—PTGS2—uterus—ovarian cancer	0.00369	0.0132	CbGeAlD
Bismuth Subsalicylate—Weight increased—Topotecan—ovarian cancer	0.00365	0.00637	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—ovarian cancer	0.00362	0.00631	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—ovarian cancer	0.0036	0.00629	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Chlorambucil—ovarian cancer	0.00358	0.00626	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Docetaxel—ovarian cancer	0.00357	0.00623	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—ovarian cancer	0.00356	0.0128	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Paclitaxel—ovarian cancer	0.00351	0.00612	CcSEcCtD
Bismuth Subsalicylate—PTGS1—female reproductive system—ovarian cancer	0.00347	0.0125	CbGeAlD
Bismuth Subsalicylate—Erythema multiforme—Chlorambucil—ovarian cancer	0.00341	0.00595	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Topotecan—ovarian cancer	0.00337	0.00588	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Paclitaxel—ovarian cancer	0.00336	0.00586	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—ovarian cancer	0.00335	0.00584	CcSEcCtD
Bismuth Subsalicylate—PTGS2—female reproductive system—ovarian cancer	0.00332	0.0119	CbGeAlD
Bismuth Subsalicylate—Lightheadedness—Paclitaxel—ovarian cancer	0.00329	0.00574	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Docetaxel—ovarian cancer	0.00327	0.00571	CcSEcCtD
Bismuth Subsalicylate—PTGS1—female gonad—ovarian cancer	0.00316	0.0113	CbGeAlD
Bismuth Subsalicylate—Hepatitis—Melphalan—ovarian cancer	0.00314	0.00548	CcSEcCtD
Bismuth Subsalicylate—PTGS1—vagina—ovarian cancer	0.00314	0.0113	CbGeAlD
Bismuth Subsalicylate—PTGS2—bone marrow—ovarian cancer	0.00313	0.0112	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Paclitaxel—ovarian cancer	0.0031	0.00541	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Epirubicin—ovarian cancer	0.00302	0.00528	CcSEcCtD
Bismuth Subsalicylate—PTGS2—female gonad—ovarian cancer	0.00302	0.0108	CbGeAlD
Bismuth Subsalicylate—PTGS2—vagina—ovarian cancer	0.003	0.0108	CbGeAlD
Bismuth Subsalicylate—Deafness—Paclitaxel—ovarian cancer	0.00298	0.00521	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Docetaxel—ovarian cancer	0.00297	0.00519	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—ovarian cancer	0.00297	0.00518	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Docetaxel—ovarian cancer	0.00285	0.00497	CcSEcCtD
Bismuth Subsalicylate—PTGS1—testis—ovarian cancer	0.0028	0.01	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—ovarian cancer	0.0028	0.00488	CcSEcCtD
Bismuth Subsalicylate—Lightheadedness—Docetaxel—ovarian cancer	0.00279	0.00487	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—ovarian cancer	0.00275	0.00479	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Paclitaxel—ovarian cancer	0.00272	0.00475	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Paclitaxel—ovarian cancer	0.00268	0.00468	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Docetaxel—ovarian cancer	0.00262	0.00458	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—ovarian cancer	0.00259	0.00453	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Chlorambucil—ovarian cancer	0.00258	0.00451	CcSEcCtD
Bismuth Subsalicylate—Infection—Chlorambucil—ovarian cancer	0.00254	0.00444	CcSEcCtD
Bismuth Subsalicylate—Deafness—Docetaxel—ovarian cancer	0.00253	0.00441	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Chlorambucil—ovarian cancer	0.00244	0.00426	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Paclitaxel—ovarian cancer	0.00244	0.00425	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—ovarian cancer	0.00241	0.0042	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—ovarian cancer	0.0024	0.00419	CcSEcCtD
Bismuth Subsalicylate—Erythema—Vinorelbine—ovarian cancer	0.00239	0.00417	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Docetaxel—ovarian cancer	0.00231	0.00403	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Docetaxel—ovarian cancer	0.00227	0.00396	CcSEcCtD
Bismuth Subsalicylate—Infection—Topotecan—ovarian cancer	0.00226	0.00395	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Chlorambucil—ovarian cancer	0.00225	0.00393	CcSEcCtD
Bismuth Subsalicylate—Oedema—Melphalan—ovarian cancer	0.00223	0.00389	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Doxorubicin—ovarian cancer	0.00223	0.00389	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Chlorambucil—ovarian cancer	0.00223	0.00388	CcSEcCtD
Bismuth Subsalicylate—Infection—Melphalan—ovarian cancer	0.00222	0.00387	CcSEcCtD
Bismuth Subsalicylate—Pain—Chlorambucil—ovarian cancer	0.00219	0.00382	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Topotecan—ovarian cancer	0.00217	0.00379	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Melphalan—ovarian cancer	0.00213	0.00371	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Chlorambucil—ovarian cancer	0.00211	0.00368	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Paclitaxel—ovarian cancer	0.0021	0.00366	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Docetaxel—ovarian cancer	0.00207	0.00361	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Chlorambucil—ovarian cancer	0.00203	0.00355	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—ovarian cancer	0.00203	0.00728	CbGeAlD
Bismuth Subsalicylate—Body temperature increased—Chlorambucil—ovarian cancer	0.00202	0.00353	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—ovarian cancer	0.00201	0.0035	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Topotecan—ovarian cancer	0.00201	0.0035	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Topotecan—ovarian cancer	0.00198	0.00346	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Melphalan—ovarian cancer	0.00196	0.00343	CcSEcCtD
Bismuth Subsalicylate—Pain—Topotecan—ovarian cancer	0.00195	0.0034	CcSEcCtD
Bismuth Subsalicylate—Constipation—Topotecan—ovarian cancer	0.00195	0.0034	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymph node—ovarian cancer	0.00194	0.00696	CbGeAlD
Bismuth Subsalicylate—Decreased appetite—Melphalan—ovarian cancer	0.00194	0.00339	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Paclitaxel—ovarian cancer	0.00194	0.00338	CcSEcCtD
Bismuth Subsalicylate—Infection—Vinorelbine—ovarian cancer	0.00194	0.00338	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—ovarian cancer	0.00192	0.00335	CcSEcCtD
Bismuth Subsalicylate—Pain—Melphalan—ovarian cancer	0.00191	0.00333	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—ovarian cancer	0.0019	0.00332	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Topotecan—ovarian cancer	0.00188	0.00328	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Vinorelbine—ovarian cancer	0.00186	0.00324	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—ovarian cancer	0.00186	0.00324	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Chlorambucil—ovarian cancer	0.00181	0.00316	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Topotecan—ovarian cancer	0.00181	0.00316	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Topotecan—ovarian cancer	0.0018	0.00314	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Docetaxel—ovarian cancer	0.00178	0.0031	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—ovarian cancer	0.00178	0.0031	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Melphalan—ovarian cancer	0.00177	0.00309	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—ovarian cancer	0.00177	0.00309	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—ovarian cancer	0.00176	0.00307	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Chlorambucil—ovarian cancer	0.00175	0.00306	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Paclitaxel—ovarian cancer	0.00175	0.00305	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Paclitaxel—ovarian cancer	0.00172	0.003	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Vinorelbine—ovarian cancer	0.00169	0.00296	CcSEcCtD
Bismuth Subsalicylate—Pain—Vinorelbine—ovarian cancer	0.00167	0.00291	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vinorelbine—ovarian cancer	0.00167	0.00291	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Docetaxel—ovarian cancer	0.00164	0.00287	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—ovarian cancer	0.00164	0.00286	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Chlorambucil—ovarian cancer	0.00163	0.00284	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Topotecan—ovarian cancer	0.00161	0.00281	CcSEcCtD
Bismuth Subsalicylate—Erythema—Paclitaxel—ovarian cancer	0.00161	0.0028	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Vinorelbine—ovarian cancer	0.00161	0.0028	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Melphalan—ovarian cancer	0.00158	0.00276	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Paclitaxel—ovarian cancer	0.00157	0.00275	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Docetaxel—ovarian cancer	0.00156	0.00273	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Topotecan—ovarian cancer	0.00156	0.00272	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—ovarian cancer	0.00156	0.00272	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Vinorelbine—ovarian cancer	0.00155	0.0027	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Vinorelbine—ovarian cancer	0.00154	0.00269	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—ovarian cancer	0.00153	0.00267	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Melphalan—ovarian cancer	0.00153	0.00266	CcSEcCtD
Bismuth Subsalicylate—Nausea—Chlorambucil—ovarian cancer	0.00152	0.00265	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Topotecan—ovarian cancer	0.00151	0.00263	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Docetaxel—ovarian cancer	0.00148	0.00258	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Topotecan—ovarian cancer	0.00145	0.00253	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—ovarian cancer	0.00144	0.00251	CcSEcCtD
Bismuth Subsalicylate—Rash—Topotecan—ovarian cancer	0.00144	0.00251	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Topotecan—ovarian cancer	0.00144	0.00251	CcSEcCtD
Bismuth Subsalicylate—Headache—Topotecan—ovarian cancer	0.00143	0.00249	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Melphalan—ovarian cancer	0.00142	0.00248	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—ovarian cancer	0.00142	0.00247	CcSEcCtD
Bismuth Subsalicylate—Rash—Melphalan—ovarian cancer	0.00141	0.00246	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Melphalan—ovarian cancer	0.00141	0.00245	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—ovarian cancer	0.00139	0.00243	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Vinorelbine—ovarian cancer	0.00138	0.00241	CcSEcCtD
Bismuth Subsalicylate—Erythema—Docetaxel—ovarian cancer	0.00136	0.00238	CcSEcCtD
Bismuth Subsalicylate—Nausea—Topotecan—ovarian cancer	0.00135	0.00236	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vinorelbine—ovarian cancer	0.00133	0.00233	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Docetaxel—ovarian cancer	0.00133	0.00233	CcSEcCtD
Bismuth Subsalicylate—Nausea—Melphalan—ovarian cancer	0.00133	0.00231	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Paclitaxel—ovarian cancer	0.00132	0.00231	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—ovarian cancer	0.00132	0.0023	CcSEcCtD
Bismuth Subsalicylate—Oedema—Paclitaxel—ovarian cancer	0.00131	0.00229	CcSEcCtD
Bismuth Subsalicylate—Infection—Paclitaxel—ovarian cancer	0.0013	0.00227	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vinorelbine—ovarian cancer	0.00129	0.00225	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—ovarian cancer	0.00129	0.00225	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Paclitaxel—ovarian cancer	0.00125	0.00218	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vinorelbine—ovarian cancer	0.00124	0.00216	CcSEcCtD
Bismuth Subsalicylate—Rash—Vinorelbine—ovarian cancer	0.00123	0.00215	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vinorelbine—ovarian cancer	0.00123	0.00214	CcSEcCtD
Bismuth Subsalicylate—Headache—Vinorelbine—ovarian cancer	0.00122	0.00213	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—ovarian cancer	0.00122	0.00213	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—ovarian cancer	0.0012	0.00209	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—ovarian cancer	0.00118	0.00205	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Paclitaxel—ovarian cancer	0.00117	0.00203	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vinorelbine—ovarian cancer	0.00116	0.00202	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Paclitaxel—ovarian cancer	0.00115	0.00201	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Paclitaxel—ovarian cancer	0.00114	0.00199	CcSEcCtD
Bismuth Subsalicylate—Pain—Paclitaxel—ovarian cancer	0.00112	0.00196	CcSEcCtD
Bismuth Subsalicylate—Constipation—Paclitaxel—ovarian cancer	0.00112	0.00196	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Docetaxel—ovarian cancer	0.00112	0.00196	CcSEcCtD
Bismuth Subsalicylate—Oedema—Docetaxel—ovarian cancer	0.00111	0.00194	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—ovarian cancer	0.00111	0.00194	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—ovarian cancer	0.00111	0.00194	CcSEcCtD
Bismuth Subsalicylate—Infection—Docetaxel—ovarian cancer	0.0011	0.00193	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—ovarian cancer	0.00109	0.0019	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Paclitaxel—ovarian cancer	0.00108	0.00189	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Docetaxel—ovarian cancer	0.00106	0.00185	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—ovarian cancer	0.00106	0.00184	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Paclitaxel—ovarian cancer	0.00104	0.00182	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Paclitaxel—ovarian cancer	0.00104	0.00181	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—ovarian cancer	0.00103	0.00179	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—ovarian cancer	0.000998	0.00174	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Docetaxel—ovarian cancer	0.000988	0.00172	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—ovarian cancer	0.000984	0.00172	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Docetaxel—ovarian cancer	0.000978	0.00171	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—ovarian cancer	0.000976	0.0017	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Docetaxel—ovarian cancer	0.000966	0.00169	CcSEcCtD
Bismuth Subsalicylate—Pain—Docetaxel—ovarian cancer	0.00095	0.00166	CcSEcCtD
Bismuth Subsalicylate—Constipation—Docetaxel—ovarian cancer	0.00095	0.00166	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Paclitaxel—ovarian cancer	0.000928	0.00162	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—ovarian cancer	0.000923	0.00161	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—ovarian cancer	0.000919	0.0016	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Docetaxel—ovarian cancer	0.000916	0.0016	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—ovarian cancer	0.00091	0.00159	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—ovarian cancer	0.000899	0.00157	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Paclitaxel—ovarian cancer	0.000897	0.00157	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Docetaxel—ovarian cancer	0.000879	0.00153	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Paclitaxel—ovarian cancer	0.000867	0.00151	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—ovarian cancer	0.00085	0.00148	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Paclitaxel—ovarian cancer	0.000834	0.00146	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—ovarian cancer	0.000832	0.00145	CcSEcCtD
Bismuth Subsalicylate—Rash—Paclitaxel—ovarian cancer	0.000827	0.00144	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Paclitaxel—ovarian cancer	0.000826	0.00144	CcSEcCtD
Bismuth Subsalicylate—Headache—Paclitaxel—ovarian cancer	0.000821	0.00143	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Docetaxel—ovarian cancer	0.000786	0.00137	CcSEcCtD
Bismuth Subsalicylate—Nausea—Paclitaxel—ovarian cancer	0.000779	0.00136	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Docetaxel—ovarian cancer	0.00076	0.00133	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—ovarian cancer	0.000756	0.00132	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—ovarian cancer	0.00075	0.00131	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—ovarian cancer	0.000745	0.0013	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Docetaxel—ovarian cancer	0.000735	0.00128	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Epirubicin—ovarian cancer	0.000715	0.00125	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Docetaxel—ovarian cancer	0.000707	0.00123	CcSEcCtD
Bismuth Subsalicylate—Rash—Docetaxel—ovarian cancer	0.000701	0.00122	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Docetaxel—ovarian cancer	0.0007	0.00122	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—ovarian cancer	0.000699	0.00122	CcSEcCtD
Bismuth Subsalicylate—Headache—Docetaxel—ovarian cancer	0.000696	0.00122	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—ovarian cancer	0.000694	0.00121	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—ovarian cancer	0.000689	0.0012	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Epirubicin—ovarian cancer	0.000666	0.00116	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—ovarian cancer	0.000661	0.00115	CcSEcCtD
Bismuth Subsalicylate—Nausea—Docetaxel—ovarian cancer	0.00066	0.00115	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—ovarian cancer	0.00066	0.00115	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—ovarian cancer	0.000652	0.00114	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—ovarian cancer	0.000641	0.00112	CcSEcCtD
Bismuth Subsalicylate—Constipation—Epirubicin—ovarian cancer	0.000641	0.00112	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—ovarian cancer	0.000618	0.00108	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—ovarian cancer	0.000617	0.00108	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—ovarian cancer	0.000611	0.00107	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—ovarian cancer	0.000603	0.00105	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—ovarian cancer	0.000596	0.00104	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—ovarian cancer	0.000593	0.00104	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—ovarian cancer	0.000593	0.00104	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—ovarian cancer	0.000593	0.00103	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—ovarian cancer	0.000572	0.000998	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000553	0.00373	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Doxorubicin—ovarian cancer	0.000551	0.000962	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—ovarian cancer	0.000548	0.000957	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000538	0.00363	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—SOD1—ovarian cancer	0.000536	0.00362	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Epirubicin—ovarian cancer	0.00053	0.000926	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	0.00052	0.00351	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—ovarian cancer	0.000513	0.000895	CcSEcCtD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—ovarian cancer	0.000511	0.00345	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP1B1—ovarian cancer	0.000508	0.00342	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—SOD1—ovarian cancer	0.000497	0.00335	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Epirubicin—ovarian cancer	0.000496	0.000865	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.000494	0.00333	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—CAV1—ovarian cancer	0.000492	0.00332	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	0.000492	0.00332	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Doxorubicin—ovarian cancer	0.000491	0.000857	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Epirubicin—ovarian cancer	0.000477	0.000832	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000475	0.0032	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—ovarian cancer	0.000475	0.000828	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	0.000474	0.00319	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Epirubicin—ovarian cancer	0.000473	0.000825	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—ovarian cancer	0.000472	0.000824	CcSEcCtD
Bismuth Subsalicylate—Headache—Epirubicin—ovarian cancer	0.00047	0.00082	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	0.000468	0.00316	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Doxorubicin—ovarian cancer	0.000459	0.000801	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	0.000453	0.00306	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	0.000453	0.00305	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CG—ovarian cancer	0.000448	0.00302	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000448	0.00302	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Epirubicin—ovarian cancer	0.000445	0.000777	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Doxorubicin—ovarian cancer	0.000441	0.00077	CcSEcCtD
Bismuth Subsalicylate—Rash—Doxorubicin—ovarian cancer	0.000437	0.000763	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—ovarian cancer	0.000437	0.000763	CcSEcCtD
Bismuth Subsalicylate—Headache—Doxorubicin—ovarian cancer	0.000435	0.000758	CcSEcCtD
Bismuth Subsalicylate—Nausea—Doxorubicin—ovarian cancer	0.000412	0.000719	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	0.000411	0.00277	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000407	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	0.000406	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	0.000406	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CD—ovarian cancer	0.000394	0.00266	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000392	0.00264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000387	0.00261	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.000378	0.00255	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000372	0.00251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.00037	0.0025	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.00037	0.00249	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	0.000351	0.00237	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.00035	0.00236	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000349	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CB—ovarian cancer	0.000344	0.00232	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	0.000332	0.00224	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SPARC—ovarian cancer	0.000327	0.00221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HSD17B6—ovarian cancer	0.000321	0.00216	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—RAD51C—ovarian cancer	0.000316	0.00213	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—IL2—ovarian cancer	0.000316	0.00213	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000315	0.00213	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000311	0.0021	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NME2—ovarian cancer	0.00031	0.00209	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000305	0.00206	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000305	0.00206	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000305	0.00206	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.0003	0.00202	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	0.000297	0.002	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL2—ovarian cancer	0.000293	0.00198	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	0.000291	0.00196	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—ovarian cancer	0.000268	0.00181	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NRAS—ovarian cancer	0.000265	0.00179	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000263	0.00177	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CHMP4C—ovarian cancer	0.000257	0.00173	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000254	0.00172	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—MAPK3—ovarian cancer	0.000254	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.000253	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000252	0.0017	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	0.000251	0.00169	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NME2—ovarian cancer	0.000246	0.00166	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.000244	0.00165	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000244	0.00164	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—MAPK1—ovarian cancer	0.000241	0.00163	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	0.000238	0.00161	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	0.000238	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	0.000234	0.00158	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000233	0.00157	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	0.000233	0.00157	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	0.000228	0.00154	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—ovarian cancer	0.000228	0.00154	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	0.000228	0.00154	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BCL9—ovarian cancer	0.000222	0.0015	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	0.000222	0.0015	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.00022	0.00148	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.00022	0.00148	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	0.000216	0.00146	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	0.000216	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000214	0.00144	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—ovarian cancer	0.000214	0.00144	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—IL6—ovarian cancer	0.000213	0.00144	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—IL6—ovarian cancer	0.000212	0.00143	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CA—ovarian cancer	0.000209	0.00141	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000209	0.00141	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—ovarian cancer	0.000204	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—ovarian cancer	0.000203	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYTB—ovarian cancer	0.0002	0.00135	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NME2—ovarian cancer	0.000199	0.00134	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000195	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—ovarian cancer	0.000194	0.00131	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000193	0.0013	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—ovarian cancer	0.000188	0.00127	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	0.000184	0.00124	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	0.000183	0.00123	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	0.000178	0.0012	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—BRIP1—ovarian cancer	0.000174	0.00118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPP1CC—ovarian cancer	0.000174	0.00118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	0.000174	0.00117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	0.000174	0.00117	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL6—ovarian cancer	0.000172	0.00116	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—AKT1—ovarian cancer	0.000171	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000171	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.00017	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	0.000169	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SPARC—ovarian cancer	0.000169	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000169	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PPP1CC—ovarian cancer	0.000165	0.00111	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	0.000158	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYTB—ovarian cancer	0.000158	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000158	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000155	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000155	0.00104	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000151	0.00102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.00015	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	0.000146	0.000986	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000146	0.000983	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	0.000139	0.000939	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPP1CC—ovarian cancer	0.000138	0.000934	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—BRIP1—ovarian cancer	0.000138	0.000934	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000138	0.000927	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	0.000137	0.000923	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	0.000134	0.000902	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000132	0.000888	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.000129	0.000867	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYTB—ovarian cancer	0.000128	0.000864	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000127	0.000857	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HDAC6—ovarian cancer	0.000125	0.000845	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000125	0.000845	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000125	0.00084	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000124	0.000838	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SOD1—ovarian cancer	0.000123	0.000827	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PPP2R1A—ovarian cancer	0.000122	0.000823	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	0.000121	0.000819	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000121	0.000817	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000118	0.000799	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000118	0.000799	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—YAP1—ovarian cancer	0.000117	0.000789	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	0.000116	0.000781	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—BRIP1—ovarian cancer	0.000112	0.000755	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPP1CC—ovarian cancer	0.000112	0.000755	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000112	0.000755	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	0.000112	0.000752	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—XIAP—ovarian cancer	0.000109	0.000733	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SMARCA4—ovarian cancer	0.000106	0.000714	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EREG—ovarian cancer	0.000103	0.000697	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000103	0.000693	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	0.000102	0.000686	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000101	0.00068	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	9.95e-05	0.000671	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	9.81e-05	0.000661	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—FASN—ovarian cancer	9.54e-05	0.000643	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	9.48e-05	0.000639	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC5A5—ovarian cancer	9.38e-05	0.000632	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—YAP1—ovarian cancer	9.29e-05	0.000626	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.19e-05	0.00062	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC2A1—ovarian cancer	9.06e-05	0.000611	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FASN—ovarian cancer	9.04e-05	0.00061	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PARP1—ovarian cancer	9e-05	0.000607	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CAV1—ovarian cancer	8.97e-05	0.000605	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	8.97e-05	0.000604	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.87e-05	0.000598	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP1B1—ovarian cancer	8.69e-05	0.000586	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SLC2A1—ovarian cancer	8.59e-05	0.000579	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	8.53e-05	0.000575	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	8.4e-05	0.000566	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CG—ovarian cancer	8.17e-05	0.000551	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.16e-05	0.00055	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.08e-05	0.000545	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPP2R1A—ovarian cancer	7.7e-05	0.000519	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.67e-05	0.000517	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—FASN—ovarian cancer	7.57e-05	0.00051	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—YAP1—ovarian cancer	7.51e-05	0.000507	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC5A5—ovarian cancer	7.45e-05	0.000502	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.44e-05	0.000501	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	7.4e-05	0.000499	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PPP2R1A—ovarian cancer	7.3e-05	0.000492	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC2A1—ovarian cancer	7.19e-05	0.000485	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CD—ovarian cancer	7.18e-05	0.000484	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCB1—ovarian cancer	7.15e-05	0.000482	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.04e-05	0.000475	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMS—ovarian cancer	7.03e-05	0.000474	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP1B1—ovarian cancer	6.9e-05	0.000465	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.54e-05	0.000441	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CB—ovarian cancer	6.26e-05	0.000422	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—FASN—ovarian cancer	6.13e-05	0.000413	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPP2R1A—ovarian cancer	6.12e-05	0.000412	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.09e-05	0.00041	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	6.05e-05	0.000408	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC5A5—ovarian cancer	6.03e-05	0.000406	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC2A1—ovarian cancer	5.82e-05	0.000392	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—ovarian cancer	5.8e-05	0.000391	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2—ovarian cancer	5.75e-05	0.000388	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.7e-05	0.000384	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCB1—ovarian cancer	5.68e-05	0.000383	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CAV1—ovarian cancer	5.66e-05	0.000382	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP1B1—ovarian cancer	5.58e-05	0.000376	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMS—ovarian cancer	5.58e-05	0.000376	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.41e-05	0.000365	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CAV1—ovarian cancer	5.37e-05	0.000362	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CG—ovarian cancer	5.16e-05	0.000348	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6ST—ovarian cancer	5.09e-05	0.000343	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPP2R1A—ovarian cancer	4.95e-05	0.000334	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.92e-05	0.000332	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APC—ovarian cancer	4.89e-05	0.00033	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—ovarian cancer	4.89e-05	0.000329	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—ovarian cancer	4.83e-05	0.000325	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK3—ovarian cancer	4.62e-05	0.000312	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCB1—ovarian cancer	4.59e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CD—ovarian cancer	4.53e-05	0.000306	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMS—ovarian cancer	4.51e-05	0.000304	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CAV1—ovarian cancer	4.49e-05	0.000303	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK1—ovarian cancer	4.4e-05	0.000296	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CD—ovarian cancer	4.3e-05	0.00029	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.29e-05	0.000289	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—ovarian cancer	4.15e-05	0.00028	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CG—ovarian cancer	4.09e-05	0.000276	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CB—ovarian cancer	3.95e-05	0.000266	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—ovarian cancer	3.82e-05	0.000257	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERBB2—ovarian cancer	3.8e-05	0.000256	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTOR—ovarian cancer	3.75e-05	0.000253	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CB—ovarian cancer	3.75e-05	0.000253	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—ovarian cancer	3.69e-05	0.000249	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CAV1—ovarian cancer	3.64e-05	0.000245	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CD—ovarian cancer	3.6e-05	0.000243	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—ovarian cancer	3.53e-05	0.000238	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1B—ovarian cancer	3.51e-05	0.000237	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.47e-05	0.000234	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—ovarian cancer	3.41e-05	0.00023	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—ovarian cancer	3.32e-05	0.000224	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CG—ovarian cancer	3.31e-05	0.000223	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—ovarian cancer	3.24e-05	0.000218	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CB—ovarian cancer	3.14e-05	0.000211	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—ovarian cancer	3.12e-05	0.00021	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CD—ovarian cancer	2.91e-05	0.000196	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT3—ovarian cancer	2.89e-05	0.000195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—ovarian cancer	2.89e-05	0.000195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAPK3—ovarian cancer	2.77e-05	0.000186	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—ovarian cancer	2.71e-05	0.000183	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—ovarian cancer	2.69e-05	0.000181	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAPK1—ovarian cancer	2.63e-05	0.000177	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—ovarian cancer	2.63e-05	0.000177	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CB—ovarian cancer	2.54e-05	0.000171	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—ovarian cancer	2.49e-05	0.000168	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.41e-05	0.000162	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—ovarian cancer	2.28e-05	0.000154	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—ovarian cancer	2.19e-05	0.000148	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—ovarian cancer	2.11e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6—ovarian cancer	2.02e-05	0.000136	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—ovarian cancer	1.97e-05	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—ovarian cancer	1.91e-05	0.000129	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—ovarian cancer	1.87e-05	0.000126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—ovarian cancer	1.56e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—ovarian cancer	1.55e-05	0.000104	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—ovarian cancer	1.26e-05	8.52e-05	CbGpPWpGaD
